Advertisement
News
Advertisement

Dr. Eva Feldman, Principal Investigator, Presents Interim Safety Results for Neuralstem ALS Trial

Tue, 04/12/2011 - 5:35am
Bio-Medicine.Org

ROCKVILLE, Md., April 12, 2011 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced that Eva Feldman, M.D., Ph.D., Principal Investigator of the Phase I safety trial of Neuralstem's human spinal cord stem cells (HSSC) in amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), and unpaid Neuralstem consultant, presented interim safety data on the first nine patients. Dr. Feldman reported yesterday at the American Academy of Neurology (AAN American Academy of Neurology (AAN) Annual Meeting (http://www.aan.com/go/am11) that all nine ALS patients remain alive and that there were no unresolved serious adverse reactions related to surgery. Of the three ambulatory patients who were treated, all remain ambulatory with no serious adverse events secondary to surgery.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO)

"We are delighted. This data demonstrates it is feasible to transplant stem cells directly into the spinal cord of patients with ALS using the procedure and device we developed for this trial," commented Dr. Feldman, who is also Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health System. "This groundbreaking work has never been done before, and we are thrilled that it can be done safely."

In this group of nine male patients, ranging in age from 37-to-66 years, with ALS  duration at the time of surgery ranging from 1-to-12 years, the first six were non-ambulatory with complete paralysis. Of these, four out of six experienced transient neuropathic pain in the spinal dermatomes near the injected area within 24 hours of the procedure, which resolved with no treatment. Three out of the six experienced adverse events secondary to immunosupp

'/>"/>

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading